- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.09. | Roche, Ionis RNA drug scores in kidney disease study | ||
| 23.09. | 9 pharma leaders sound 'alarm bells' on biotech's decline in Europe | ||
| 22.09. | Amgen reports a Phase 3 win with Sjögren's drug candidate | ||
| 22.09. | Viking shares surge on updated obesity drug data | ||
| 22.09. | Celldex sinks as safety concerns cloud immune drug results | ||
| 22.09. | An orexin drug's 'proof-of-concept' in ADHD; Cue's 'unwarranted' share slide | ||
| 22.09. | A hidden tradeoff in Trump's drug pricing deals | ||
| 21.09. | Beacon eye gene therapy hits mark in late-stage study | ||
| 21.09. | Novo talks up drug launches in effort to win back investors | ||
| 21.09. | Telix buys ITM in bid to create a 'radiopharmaceutical powerhouse' | ||
| 21.09. | How J&J paved the way for Compass' coming psychedelic drug launch | ||
| 21.09. | Are healthcare systems really ready for GLP-1s? | ||
| 21.09. | Behind the outcomes: How whole-patient support is reshaping oncology care | ||
| 18.09. | Xenon shares fall following depression trial pause | ||
| 18.09. | This week in charts: GSK's China deals, the $300M IPO club and selling the news | ||
| 18.09. | Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug | ||
| 18.09. | Electra Therapeutics amasses $350M in biotech's latest big IPO | ||
| 17.09. | Novo partners with Orbis, deepening investment in oral peptide drugs | ||
| 17.09. | North Immunology joins biotech reverse merger boom with Aethlon deal | ||
| 17.09. | Roche, Dualitas team up to find bispecific drugs for immune diseases | ||
| 16.09. | Novartis to pay $125M for blood-brain barrier crossing platform | ||
| 16.09. | Novo looks to Anthropic's AI models to 'supercharge' drug development | ||
| 16.09. | Sling banks $123M for an experimental thyroid eye disease pill | ||
| 15.09. | FDA clears first generic radioligand drug; Sionna turns to layoffs | ||
| 15.09. | WCLC '26: A new 'ADC era,' China questions and AstraZeneca's spotlight |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.